Targeted therapy: What does it mean? A physician point of view;Qu'est-ce qu'une thérapie ciblée? Le point de vue du clinicien

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Spano, Jean Philippe ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Targeted therapies

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; TAMOXIFEN; TRASTUZUMAB;

ANGIOGENESIS; APOPTOSIS; ATTENTION; BRONCHUS CANCER; CANCER PATIENT; CARCINOGENESIS; COLORECTAL CANCER; COMPREHENSION; DISEASE MARKER; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENT; EUROPE; HUMAN; METASTASIS; MOLECULAR MECHANICS; MOLECULE; MONOTHERAPY; ONCOLOGY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT IDENTIFICATION; PHARMACOGENOMICS; PHYSICIAN; PREDICTION; PROTEOMICS; RESEARCH; REVIEW; SCREENING; TECHNOLOGY; TUMOR CELL; TUMOR GROWTH; UNITED STATES;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36248940788     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0435     Document Type: Review

References (17)

1. Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000 ; 60 : 1-14.
2. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002 ; 7 : 2-8.
3. Spano JP, Milano G, Baselga J. EGFR/VEGF signalling pathway in colorectal cancer : the way we are! Bull Cancer 2005 ; 92 : S3-S4.
4. Blay JY. Les thérapeutiques ciblées. Oncologie 2003 ; 5 : 351-6.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
6. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999 ; 59 : 1935-40.
7. L'Allemain G. La famille des récepteurs HER-ErbB et ses ligands : mécanismes d'activation, signalisations et dérégulations dans le cancer. Bull Cancer 2003 ; 90 : S179-S185.
8. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis : signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997 ; 410 : 83-6.
9. Savave DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002 ; 346 : 683-93.
10. Belkacemi Y, Gligorov J, Mauriac L, Azria D. Cancer du sein surexprimant l'oncoprotéine HER2/Neu : comment prescrire le trastuzumab en situation adjuvante? Bull Cancer 2006 ; 93 : 991-9.
11. Hortobagyi G. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005 ; 353 : 1734-6.
12. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002 ; 2 : 727-39.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 ; 23 : 1011-27.
14. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006 ; 107 : 2617-21.
15. Verweij J, van Oosterom AT, Blay Y, et al. Imatinib (Glivec) an active agent for gastrointestinal stromal tumors (GIST), but not for other soft tissue sarcoma subtypes not characterized for KIT and PDGFR expression, results of EORTC phase II studies. Eur J Cancer 2003 ; 39 : 2006-11.
16. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003 ; 30 : 3-8.
17. Hampton T. Targeted cancer therapies lagging. JAMA 2006 ; 296 : 1951-2.